By jurisdiction
United States (FDA)
Every compound we track that has a recorded status under United States (FDA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| BPC-157 | Under review | Not on the 503A Bulks List; under active PCAC review, meeting July 23-24, 2026. |
| Semax | Under review | Never in Category 1; Category 2 nomination withdrawn; before PCAC July 24, 2026. |
| TB-500 (Thymosin Beta-4) | Under review | Never in Category 1; removed from Category 2 in April 2026; before PCAC July 23-24, 2026 (Docket FDA-2025-N-6895). |
| CJC-1295 | In limbo | Removed from Category 2 (~Sept 2024); PCAC voted against inclusion Dec 4, 2024; not on the 503A list; no USP monograph. |
| GHK-Cu | In limbo | Topical route ≈ Category 1; injectable route removed from Category 2, not on the 503A list; PCAC review before Feb 2027. |
| Ipamorelin | In limbo | Removed from Category 2 (~Sept 2024); PCAC voted against 503A inclusion Oct 29, 2024; not on any bulks list; no separate ban. |
| Melanotan II | In limbo | Not on Category 1 / the 503A list; being moved out of Category 2; PCAC review before Feb 2027. Not DEA-scheduled. |
| NAD+ | In limbo | Proposed for non-inclusion (2019); no final rule and no ban; oral sold as a supplement; injectable compounded in a gray area. |
| Selank | In limbo | Removed from Category 2 (~Sept 2024); never in Category 1; not on the 503A list; no scheduled PCAC review. |
| Thymosin Alpha-1 | In limbo | Removed from Category 2 (2024); PCAC declined to recommend it on Dec 4, 2024; not on the 503A list; no approved U.S. product. |
| Semaglutide (compounded) | Restricted | Enforcement discretion ended Apr 22, 2025 (503A) / May 22, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow patient-specific 503A exception remains. |
| Tirzepatide (compounded) | Restricted | Enforcement discretion ended Feb 18, 2025 (503A) / Mar 19, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow 503A exception remains. |
| Sermorelin | Compounding-legal | Category 1 of the interim 503A list; compoundable with a valid prescription under enforcement discretion. Previously approved as Geref. |